newsfilter
← Latest News
GlobeNewswire·

Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment

Planned Review of Standard Deviation Demonstrates No Need to Increase Size of Ongoing LEVEL Study LEVEL On Track to Complete Enrollment in First Half of 2026; Topline Data Expected in Second Half of 2026 Global Phase 3